Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT-P51 vs Keytruda in previously untreated metastatic non-squamous NSCLC
NCT06939595Phase 3Active, not recruiting
- Sponsor
- Celltrion
- Start
- Jan 2025
- Primary completion
- Feb 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of CT-P51 in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC), sponsored by Celltrion. Started Jan 2025; status: active, not recruiting.
02
Drugs
CT-P51
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT06939595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06939595.